Moderna faces regulatory threats to its coronavirus franchise and struggles with vaccine traction. Despite this, the biotech has exciting clinical programs. With shares down over 90% from their peak, the company’s revenue and earnings have dropped post-pandemic. Can Moderna rebound and surpass previous highs? Investors should closely monitor key developments.

Moderna generates annual revenue from Spikevax, with $114 million in Q2 sales. Regulatory changes in the U.S. could impact vaccine sales. Approval for mResvia for RSV in adults 60+ has had minimal sales, but recent label expansions could boost revenue. Investors should watch how these factors affect financial results.

Late-stage pipeline programs, like mRNA-1010 for influenza and mRNA-4157 for cancer, show promise. Moderna’s flu vaccine could address low efficacy issues, while cancer vaccine studies have shown significant risk reduction. Progress on mRNA-1647 for CMV could also impact the company’s stock positively.

Moderna’s deep pipeline and revenue from approved products provide potential for growth. The biotech’s cost-cutting efforts aim to navigate economic challenges. While the stock carries above-average risk due to uncertainty in product sales and clinical setbacks, it also offers considerable upside. Investors comfortable with risk should consider Moderna.

Read more at Yahoo Finance: The 3 Things That Matter for Moderna Now